Summit Therapeutics launches global Phase III HARMONi-GI3 trial as ivonescimab enters colorectal cancer race

Summit Therapeutics has taken another bold step in its immuno-oncology ambitions by launching the global Phase III HARMONi-GI3 study to evaluate ivonescimab in first-line colorectal cancer. The move expands the drug’s late-stage pipeline beyond its lung cancer focus and signals the company’s determination to establish ivonescimab as a multi-tumor therapeutic platform rather than a single-indication success story. For Summit, which trades on Nasdaq under the ticker SMMT, the announcement represents both scientific conviction and financial risk as investors weigh its capacity to fund simultaneous large-scale programs while maintaining momentum in its partnership with Akeso Inc.

At the heart of the decision lies Summit’s confidence in the bispecific antibody’s dual-targeting design. Ivonescimab simultaneously blocks PD-1 to reinvigorate immune response and inhibits VEGF to suppress angiogenesis—the process that fuels tumor blood supply. By merging two mechanisms within one antibody, Summit hopes to exploit cross-pathway synergy in tumor microenvironments that are both immunosuppressive and highly vascularized, such as colorectal cancers.

How Summit Therapeutics aims to position ivonescimab beyond lung cancer and validate its dual-target mechanism in a new tumor type

The rationale for HARMONi-GI3 comes from evidence gathered in Summit’s existing lung cancer trials. In the global HARMONi study, patients with EGFR-mutant non-small-cell lung cancer (NSCLC) receiving ivonescimab plus chemotherapy experienced a nearly 50 percent reduction in the risk of progression or death compared with chemotherapy alone. The improvement in progression-free survival validated the dual-target concept and provided the confidence to extend development into gastrointestinal malignancies.

By entering the first-line colorectal cancer setting, Summit is targeting one of oncology’s most competitive but high-value markets. Current standards of care rely heavily on combinations such as FOLFOX, FOLFIRI, and bevacizumab-based regimens, while immune checkpoint inhibitors are largely confined to microsatellite instability-high (MSI-H) populations. Ivonescimab’s dual-pathway action could, if successful, broaden immunotherapy utility to a much wider subset of patients.

The company is expected to pursue a biomarker-guided strategy in HARMONi-GI3, identifying molecular signatures that correlate with response to both PD-1 and VEGF blockade. If efficacy extends into microsatellite-stable (MSS) colorectal cancer—a population historically resistant to immunotherapy—the commercial and clinical implications would be significant. Such a breakthrough could shift the therapeutic hierarchy in colorectal cancer and potentially challenge existing anti-VEGF drugs as first-line anchors.

Why the Akeso partnership remains pivotal to Summit’s global trial expansion and strategic resource alignment

Summit’s collaboration with Akeso Inc., the Chinese innovator that discovered ivonescimab, remains central to the drug’s global roadmap. Under their 2022 agreement, Summit holds development and commercialization rights across the United States, Canada, Europe, and Japan, while Akeso retains rights in China and other territories. The partnership established a synchronized global framework in which both companies pursue independent regional programs but share clinical insights to accelerate approvals.

Akeso has already filed for approval of ivonescimab in China following strong data from its domestic HARMONi-2 study. That parallel progress offers Summit external validation and may help regulators assess the antibody’s consistency across ethnic and geographic cohorts. Coordinating global regulatory submissions, however, poses logistical and analytical complexity, as agencies often scrutinize cross-trial comparability when data are generated in heterogeneous populations.

To strengthen its development base, Summit has also aligned with major academic and industrial partners. Collaborations with MD Anderson Cancer Center focus on translational immunology and biomarker discovery, while research agreements with Revolution Medicines and Pfizer will test ivonescimab in combination with next-generation targeted and antibody-drug conjugate therapies. These alliances are designed to maximize the antibody’s versatility and mitigate the financial risk of single-asset dependency.

Internally, Summit has built a development infrastructure to manage simultaneous global trials. Yet such expansion carries cost pressure—especially for a mid-cap biotech whose R&D expenditure has nearly doubled year-over-year. The HARMONi-GI3 launch, therefore, underscores not only scientific ambition but also operational strain.

How investor sentiment and stock performance reflect both optimism and risk in Summit’s oncology strategy

Summit Therapeutics’ share price has mirrored the drama surrounding its data releases. In mid-2025, following strong interim progression-free survival results from HARMONi, SMMT shares briefly surged above $28, driven by investor enthusiasm for ivonescimab’s global potential. Subsequent updates that revealed regional efficacy differences and a non-significant overall survival benefit triggered corrections of over 20 percent in a single session, demonstrating how tightly investor confidence is tied to clinical consistency.

Despite volatility, insider activity has trended bullish. Summit’s executive chairman and co-chief executive officer have continued purchasing shares in the open market, signaling confidence in the long-term outlook. Analysts at Evercore ISI and JMP Securities maintain “Outperform” ratings with price targets between $34 and $40, citing differentiated biology and pipeline optionality as catalysts. However, many institutional investors still frame SMMT as a binary event stock, where success in any Phase III program could yield exponential upside, while failure could compress valuation dramatically.

From a financial standpoint, the company’s filings reflect mounting R&D and administrative expenses, prompting auditors to flag “substantial doubt” about Summit’s ability to continue as a going concern without additional financing. Management has acknowledged the challenge but pointed to multiple levers—equity issuance, partnership milestones, and potential non-dilutive funding—that could extend its runway. The company’s alignment with Akeso also provides access to ex-China manufacturing efficiencies, which may partially offset global trial costs.

Investor sentiment, therefore, hinges on clinical momentum. A strong start for HARMONi-GI3 would likely catalyze a rerating of Summit’s valuation multiples, restore credibility after the lung data debate, and reopen access to capital on more favorable terms. Conversely, any safety or efficacy setbacks could reinforce market skepticism that the PD-1/VEGF approach lacks sufficient differentiation from existing regimens.

What success or failure in HARMONi-GI3 could mean for Summit’s future in immuno-oncology and global competitiveness

The initiation of HARMONi-GI3 transforms Summit’s development pipeline into a stress test of its entire business model. If ivonescimab demonstrates meaningful benefit in first-line colorectal cancer, Summit could secure a strategic foothold in one of the largest solid-tumor markets globally, validating its multi-indication strategy and potentially setting up combination pathways in gastric, pancreatic, and hepatobiliary cancers.

Such success would also strengthen Akeso’s credibility as an emerging force in bispecific antibody engineering and open doors for future co-developed biologics targeting complex oncogenic pathways. Moreover, it could position Summit as a competitive challenger to entrenched immunotherapy players like Merck, Bristol Myers Squibb, and Roche, particularly in tumor types where PD-1 monotherapies have plateaued.

However, the downside risk is equally pronounced. A negative readout would reinforce doubts about regional translatability, exhaust capital reserves, and delay Summit’s revenue timeline by years. Given its concentrated pipeline, the company cannot afford multiple late-stage failures without significant restructuring or dilution. For now, management appears committed to aggressive execution, maintaining that ivonescimab’s differentiated pharmacology and dual-mechanism design justify the gamble.

In broader industry context, the HARMONi-GI3 study also arrives amid a renewed investor focus on antibody innovation as small-molecule pipelines face attrition. If Summit’s approach succeeds, it could revitalize confidence in dual-function biologics as next-generation checkpoint alternatives, attracting fresh institutional capital into the sector. Conversely, a setback might caution peers about overextending immunotherapy portfolios without clear mechanistic differentiation. Either way, HARMONi-GI3 will likely serve as a defining inflection point not only for Summit’s market standing but for the entire wave of companies exploring PD-1 combinations in solid tumors. The trial’s outcome will ultimately determine whether ivonescimab emerges as a cornerstone of a new immunotherapy paradigm—or a cautionary tale in the high-stakes evolution of bispecific oncology drugs.